A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE
Date Published March 17, 2026
No summary available
COM Affiliation
Funding Type
Corporate Grant (for-profit and non-profit)
Update This Listing
Help us provide the most up-to-date information about this project.
Contact UsQuestions?
For questions about these research projects please email us.
Contact Us